More incentives in the works to convince medical officers to remain in Borneo States
He also said that about 20% of the medical officers who have applied to be transferred from Sabah and Sarawak to the Peninsula states may have to stay in their current postings.
The Health Minister made this statement on Sunday (July 27) after launching the book titled 'Crisis and Community: Covid-19 in Malaysia', a compilation of essays on the Covid-19 crisis by people from all levels of society, edited by Bridget Welsh.
He asked the medical officers stationed in the Borneo States to 'give it a chance," even if they are 'reluctant at first."
It was reported that approximately 600 medical officers currently stationed in Sabah and Sarawak have applied for transfer to the Peninsula.
The Health Ministry said that this has caused difficulties in ensuring that public health services are sufficiently provided to the people in Sabah and Sarawak.
On July 24, the former chairman of the Malaysian Medical Association of Sabah branch, Dr Brandon Patrick, called for more doctors to be posted in Sabah and Sarawak, adding that incentives should be given to those posted to both states.
He expressed his support for the Sabah government's proposal to provide an additional special allowance to doctors stationed in Sabah and Sarawak.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
5 hours ago
- New Straits Times
Sexual transmission accounts for 96pct of new HIV cases in Malaysia
KUALA LUMPUR: Sexual transmission now accounts for nearly all new HIV cases in Malaysia, marking a significant shift from previous patterns of infection through needle sharing, the Dewan Rakyat was told. Health Minister Datuk Seri Dr Dzulkefly Ahmad said that in 2024, 96 per cent of new HIV infections were linked to sexual contact, with 64 per cent involving homosexual or bisexual transmission and 32 per cent through heterosexual transmission. "In 2024, a total of 3,185 new HIV cases were reported, with a notification rate of 9.4 per 100,000 population. "The majority of cases were among men, accounting for 90 per cent, compared to 10 per cent among women. "This trend marks a shift from the 1990s, when women made up only 1 per cent of cases and men 99 per cent," he said in a written parliamentary reply published today. He was responding to Tan Kok Wai (PH-Cheras), who enquired about the current status of HIV infections in the country, including the number of patients by age group and gender, as well as the main causes of transmission. Dzulkefly said 75 per cent of the cases reported last year involved youths aged between 20 and 39. "New HIV or AIDS infections in Malaysia generally recorded a 50 per cent decline between 2000 and 2009. "However, from 2010 until now, the rate of decline has slowed, registering only a 27 per cent reduction." In February, Dzulkefly said more than 60 per cent of HIV infections last year were transmitted through homosexual and bisexual relations. He said a key factor behind this increase in transmission is the inconsistent use of condoms, especially among high-risk groups.
The Star
8 hours ago
- The Star
Hepatitis C treatment can be safely shortened
A new clinical trial conducted in Malaysia has found that an eight-week regimen of ravidasvir and sofosbuvir is just as safe and effective as the standard 12-week treatment for chronic hepatitis C. This finding could accelerate efforts to scale up access to treatment in resource-limited settings by reducing treatment duration, costs and system burden. The EASE study (Evaluating Accelerated Shortened treatment for hepatitis C in Asia through real-world Evidence) was led by the Health Ministry (MOH) and conducted across 26 sites nationwide between March 2021 and March 2023. The randomised trial involved 322 patients diagnosed with chronic hepatitis C virus infection, including those with more complex medical profiles. The primary objective was to determine whether an eight-week treatment course using the fixed-dose combination of ravidasvir and sofosbuvir would achieve similar sustained virological response (SVR), compared to the standard 12-week regimen. An SVR refers to the continued absence of the hepatitis C virus in a patient's blood 12 weeks or more after they have completed treatment. It is essentially considered a virological cure for the infection. The study found no significant difference in efficacy between the two durations, with high SVR rates maintained in both arms. Safety profiles were also comparable, with no new adverse effects identified. The results were officially reported by the MOH in January (2025) and presented at the 2025 European Association for the Study of the Liver (EASL) Congress in early May in Amsterdam, the Netherlands. Ravidasvir was co-developed through a public-health partnership involving the MOH, Drugs for Neglected Diseases initiative (DNDi), Pharco Pharmaceuticals (Egypt) and Pharmaniaga Berhad (Malaysia), with key clinical trials conducted in Malaysia and Thailand. The treatment was first registered in Malaysia in 2021 and added to the World Health Organization (WHO) Essential Medicines List in 2023. While hepatitis C continues to affect approximately 50 million people globally, with only about 20% receiving treatment, high drug prices remain a barrier in many countries. A 2023 MOH study estimates 0.4% of the population in Malaysia to have hepatitis C. In line with WHO targets, Malaysia aims to eliminate the disease as a public health threat by 2030.
Focus Malaysia
17 hours ago
- Focus Malaysia
Malaysia's healthcare travel industry eyes RM12 bil by 2030
MBSB Research recently hosted the Malaysia Healthcare Travel Council (MHTC) in a roundtable dialogue recently. While MHTC focuses on the private healthcare sector, various government ministries, are involved to ensure a cohesive and supportive ecosystem for medical tourism. This multi-agency cooperation is crucial for addressing the diverse needs of the industry, from healthcare standards to visa facilitation and economic planning. Since the decline in Covid-19 prevalence, Malaysia had seen a surge in medical travellers from the Asia-Pacific region seeking treatments. In 2024, the number of medical travellers reached 1.52 mil and revenue at RM2.72 bil. For 2025, MHTC is expecting revenue to climb up to RM3 bil, attributed by a robust demand for quality and affordable care. By 2030, MHTC aims to generate over RM12 bil in revenue, supported by continuous expansion of hospital capacity, targeted promotional efforts and implementation of integrated healthcare. Medical tourism in Malaysia is not just about hospital revenue. It creates a significant ripple effect across the economy. As foreign patients and their companions travel, they spend on various services beyond medical treatments, including accommodation, transportation, dining, and entertainment. This multiplier effect is a critical driver of growth for the hospitality, tourism, and food & beverage sectors. The revenue projected at RM12 bil by 2030 solely accounts for medical-related expenses and excludes the substantial spending on other associated services. This revenue, combined with an estimated economic multiplier of 4x, demonstrates the significant financial benefits of the industry. Every region in Malaysia contributed to medical tourism. In 2024, Central Region contributed 42% of the total revenue (RM886 mil) while Northern Region contributed 41%, Southern Region contributed 12% and the others (East Coast and East Malaysia) contributed 5%. Penang remains a major hub for medical tourism, serving up to 40% of the total volume of medical tourists. Its appeal is driven by its cultural affinity with Mainland Chinese and Indonesians, as well as its strategic proximity, which is supported by high flight frequency. Despite contributing the lowest revenue, East Coast had seen a gain in tourist volumes; likely due to the support from the state tourism and its proximity to Thailand. Meanwhile, Sabah and Sarawak saw high potential for growth, if state hospital brands are well promoted and accessibility by air and land are improved. Malaysia's competitive edge in the regional medical tourism market is its highly regulated healthcare environment. This offers a distinct advantage over competitors like Thailand and attracts patients seeking a safer and more structured treatment setting. Despite the first quarter typically not being a peak period, quarter one of 2025 already recorded a significant 8% increase in revenue (RM631 mil-682 mil) and a 7% rise in traveller volume (370,000-398,000). This indicates that Malaysia still retains an undulated potential and competitiveness in medical tourism. A key advantage for Malaysia is that foreign patients are charged the same rates as locals, which incentivizes them to spend more on other industries like tourism and hospitality. However, regional disparities remain a key challenge. While Penang is a major driver of medical tourism, largely due to key institutions like Island Hospital, East Malaysia struggles to attract medical tourists because of accessibility challenges, limited flight frequency, and less-known hospitals. 'Moving forward, we expect MHTC and other travel-related agencies and sectors (hospitality, consumer and aviation) to improve accessibility, as advocated by the government under the 13th Malaysia Plan,' said MBSB Research. —Aug 6, 2025 Main image: Senior Planet
